Improving Lives: Breakthroughs & Collaborations - Research Report on Pfizer, Merck, Bristol-Myers Squibb, J&J and Lilly

 Improving Lives: Breakthroughs & Collaborations - Research Report on Pfizer,
                  Merck, Bristol-Myers Squibb, J&J and Lilly

PR Newswire

NEW YORK, March 18, 2013

NEW YORK, March 18, 2013 /PRNewswire/ --

Today, Wall Street Source announced new research reports highlighting Pfizer
Inc. (NYSE: PFE), Merck & Co., Inc. (NYSE: MRK), Bristol Myers Squibb Co.
(NYSE: BMY), Johnson & Johnson (NYSE: JNJ) and Eli Lilly & Co. (NYSE: LLY).
Today's readers may access these reports free of charge - including full price
targets, industry analysis and analyst ratings - via the links below.

Pfizer Inc. Research Report

New trial results show promising results for Inspara (eplerenone) in patients
with acute STEMI without heart failure. In randomized, double-blind REMINDER
trial involving 1, 012 patients with acute ST-segment elevation myocardial
infarction (STEMI) without a history of HF or EF, eplerenone improved the
outcome of the patients within first 24 hours of symptoms. Adding eplerenone
to standard therapy as early as within the first 24hours of symptoms reduced
heart failure-related morbidity. The REMINDER trial demonstrated a
statistically significant 42.9% relative risk reduction in the primary
endpoint with p < 0.0001 (95% confidence interval [CI] 0.439, 0.742) in
patients with acute STEMI when eplerenone was initiated within the first 24
hours of onset of symptoms. Overall, the adverse events reported in the
REMINDER trial were consistent with those already known for eplerenone,
primarily hyperkalemia. This should bring good news to patients who want
treatment with higher efficacy but with lower risks. The Full Research Report
on Pfizer Inc. - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:
[http://www.WallStSource.com/r/full_research_report/db02_PFE]

--

Merck & Co., Inc. Research Report

A collaboration between Merck and Luminex Corporation is leading to
development of a companion diagnostic device that will be evaluated to help
support patient selection for the clinical development of MK-8931, Merck's
lead investigational medicine for Alzheimer's disease. MK-8931 is a novel oral
beta amyloid precursor protein site cleaving enzyme (BACE) inhibitor.
"Evaluation of biomarkers that may provide an indicator of disease onset and
enable earlier diagnosis is an important goal toward facilitating early
intervention and potentially improving the treatment of Alzheimer's disease,"
said Darryle D. Schoepp, Ph.D., senior vice president, head of Neuroscience
and Ophthalmology at Merck Research Laboratories. "We look forward to working
with Luminex to advance our ongoing clinical development program for MK-8931."
Luminex, on the other hand, will be responsible for development, regulatory
submission and commercialization of the candidate companion diagnostic device.
The Full Research Report on Merck & Co., Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at: [http://www.WallStSource.com/r/full_research_report/400f_MRK]

--

Bristol Myers Squibb Co. Research Report

Grants totaling $175,000 was awarded to both the American Cancer Society
Eastern Division and Princeton HealthCare System (PHCS) to support
comprehensive navigation services for patients with cancer both independently
and as part of a collaborative effort among several hospitals in central New
Jersey. Navigation is now viewed as an integral part of cancer services, with
several studies linking patient navigation to improved patient outcome and
survival rates. Navigators help coordinate patients' care and guide them to
resources that can provide psychosocial support and address financial
concerns, language or cultural issues and day-to-day needs such as
transportation. "Bringing together organizations with common goals, similar
programs and potentially complimentary services can lead to efficiencies in
immediately tangible ways," says Murdo Gordon, SVP-Oncology, U.S.
Pharmaceuticals, Bristol-Myers Squibb. "With the coming changes of the
Affordable Care Act, the financial impact on organizations and individuals
will likely be profound, and the entire cancer community will need to work
together to address these concerns. Collaborative approaches, such as those
being taken by UMCPP and the American Cancer Society, which bring together
meaningful services from various providers to support a given community, is a
refreshing solution." The Full Research Report on Bristol-Myers Squibb Co. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.WallStSource.com/r/full_research_report/88a2_BMY]

--

Johnson & Johnson Research Report

Johnson & Johnson is proud to announce the opening of the Johnson & Johnson
Innovative Center in London, one of the regional hubs being established this
year in the world's leading innovation hotspots. The London innovation center
aims to accelerate the best early stage science in the world and advance the
development of new healthcare solutions "Britain has a worldwide reputation
for excellence in innovation - the investment by Johnson & Johnson here
demonstrates this and I am delighted to welcome this new center to the UK,"
says UK Secretary of State for Health Jeremy Hunt, who will be speaking at the
Innovation Expo 2013. Johnson & Johnson Chief Scientific Officer and Worldwide
Chairman, Pharmaceuticals, Paul Stoffels, MD, says, "The London Innovation
Centre is part of Johnson & Johnson's broader innovation strategy to advance
human health through collaboration with the world's leading scientists and
entrepreneurs. We are looking forward to collaborating within the UK, home to
one of the world's thriving life sciences ecosystems." Similar facilities are
also being planned in Boston, San Francisco and, later this year, Shanghai.
Each city was selected for its robust life sciences community. The Full
Research Report on Johnson & Johnson - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at: [http://www.WallStSource.com/r/full_research_report/0ba3_JNJ]

--

Eli Lilly & Co. Research Report

Eli Lilly & Co., along with Kowa Pharmaceuticals America, Inc. is pleased to
announce the results of a study evaluating the efficacy of LIVALO
(pitavastatin) 4mg compared with pravastatin 40mg in reducing low-density
lipoprotein cholesterol (LDL-C) in HIV-infected adults with high cholesterol
or dyslipidemia. The study was designed as a superiority trial for the primary
endpoint, percent reduction in LDL-C, and evaluated HIV-infected adults with
dyslipidemia; with and without viral Hepatitis B or C. Dyslipidemia is common
in people with HIV infection and HIV-infected adults are at a greater risk for
cardiovascular disease due to many factor, including lipid abnormalities.
Results showed that, after 12 weeks of therapy, pitavastatin had a
significantly greater decrease in LDL-C compared with pravastatin
(pitavastatin -49.4 mg/dL and pravastatin -33.6 mg/dL, 31% vs 21% reduction in
LDL-C, respectively, p < 0.001). As pleased they are with the results, both
companies look forward to further analysis of the data. The Full Research
Report on Eli Lilly & Co. - including full detailed breakdown, analyst ratings
and price targets - is available to download free of charge at:
[http://www.WallStSource.com/r/full_research_report/937b_LLY]

--

Consider Wall Street Source

Tired of hearing about the latest, greatest trade opportunity... only to
realize that the ship has long sailed? You need a strong, informative
community in your arsenal. Join the group that has been consistently
identifying momentous situations as they develop - long before they become the
next top news on major financial networks.

Contact: Joe Thomas
Email: press@wallstsource.com
Main: +1-310-496-8071 (North America)

SOURCE Wall Street Source